Today announced that its biopharmaceutical subsidiary, LineaRx, Inc. (“LineaRx”), has successfully completed production of its largest order in LineaRx history.
The $1.2 million order, originally announced in January 2026 with shipments completing in early May 2026, was produced at historically higher margins with zero batch failures, demonstrating the technical excellence and manufacturing reliability of the LineaDNA platform for large-scale cell-free DNA production. Notably, the Company achieved a production cadence of more than 1.5 grams per week during fulfillment of this order, a new record for LineaRx and a further demonstration of the platform’s scalability and manufacturing maturity.
“The successful completion of our largest LineaDNA order to date represents a meaningful milestone for LineaRx and for BNB Plus,” said Clay Shorrock, President and Chief Executive Officer of BNB Plus. “LineaDNA continues to demonstrate proven demand from leading genetic medicine and in vitro diagnostic developers. Our ability to consistently execute at scale underscores the strength and commercial readiness of the platform.”
Strategic Review
As previously announced on April 20, 2026, the Company’s Board of Directors authorized a formal review of strategic alternatives to maximize shareholder value. The Company continues to execute on its strategic and operating initiatives during the review process.
“As we continue our strategic alternatives review, we expect the compelling fundamentals of the LineaRx business will be central to our evaluation,” continued Shorrock.
The Company does not intend to provide updates on the strategic review until its Board of Directors has approved a specific transaction or otherwise determines that disclosure is appropriate or required by law and there can be no assurance that the review of strategic alternatives will result in any transaction being announced or consummated.
Read Also: MoneyGram and Stellar Extend Partnership to Scale Real-World Stablecoin Utility Globally
